ATAI News and Press, ATAI Life Sciences N.V. From 08/08/23

NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced results from Perception Neuroscience’s Phase 1 intravenou...

Researchers from the University of Zurich Psychiatric Hospital are comparing what happens to the human brain during meditation and hypnosis, as well as while under the effects of psychedelics. Brain changes while under the influence of drugs or during states such as hypnosis and meditation ha...

American researchers studying the effects of psychedelics on eating disorders have found that psilocybin, the main hallucinogenic agent in magic mushrooms, may be able to treat anorexia. U.S. researchers ran the small study,  which involved 10 adult women aged 18 to 40 years of age. Eat...

Research into psychedelics is increasingly revealing that these purportedly dangerous drugs may have potent mental health benefits . While modern antidepressants work by influencing the levels of hormones such as serotonin in the brain, psychedelics seem to deliver their benefits by influencin...

2023-07-16 18:00:00 ET Summary Alex Carchidi returns to update investors on the psychedelics industry. Collapse, consolidation, and why you shouldn't bet on just 1 stock. Compass Pathways' timeline for clinical trials; Atai and Cybin's recent wins. Alex Carchidi For ...

2023-07-15 04:25:01 ET Summary The memo reads that the bear market has been cancelled, and there are few who are as happy about the change in fortunes as Cathie Wood and ARK Funds. Her flagship ARKK fund, as well as other ARK family funds, have had an impressive run lately and wer...

2023-07-14 19:10:45 ET Summary A review of recent research suggests that the testing methods may have led to overly optimistic expectations. A competitive drug has been approved and appears to be making excellent commercial headway. COMPASS Pathways is short on cash but has ma...

A recent study has found that psilocybin-assisted group psychotherapy can help alleviate the mental woes of cancer patients with depression. While several treatments are designed to kill cancer cells and alleviate the physical symptoms caused by cancer, the mental distress associated with a can...

2023-07-13 12:35:00 ET Summary Will tough times continue for psychedelic stocks? Analyst Alex Carchidi shares his views on the sector and specific stocks like Compass Pathways, Atai and Cybin. Inevitability of big pharma entering the space. Listen below or on the g...

As America has become increasingly progressive in its drug policy, psychedelics have turned from relatively obscure drugs enjoyed by a niche community to potentially game-changing mental-health treatments. Studies on hallucinogenic drugs such as psilocybin (magic mushrooms), MDMA and ayahuasca ...